News

Nuwellis Appoints John Erb as Chief Executive Officer

WHO WHAT WHERE WHEN HOW John Erb Appointed as Chief Executive Officer (no longer serving in an interim capacity) Nuwellis Headquarters Effective June 27, 2025 Appointment confirmed by the Board of Directors following his interim leadership MINNEAPOLIS, July 02, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to advancing solutions in fluid management, today announced the appointment of John Erb as its Chief Executive Officer. Erb, who has served as interim CEO since February 2025, will continue to lead the company with a focus on strategic clarity, operational discipline, and sustainable growth.

07/02/2025

Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995 shares of Common Stock and Series B Warrants to purchase up to 16,666,665 shares of Common Stock with gross proceeds of approximately $5.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.

06/10/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Nuwellis, Inc. (NUWE) a buy, sell, or hold?

Nuwellis, Inc. (NUWE) can hold. Click on Rating Page for detail.

What is Nuwellis, Inc.'s stock price?

The price of Nuwellis, Inc. (NUWE) is 0.1974 and it was updated on 2025-07-03 11:00:21.

Is Nuwellis, Inc. (NUWE) overvalued or undervalued?

Currently Nuwellis, Inc. (NUWE) is in undervalued.

News

From:

To:

News
Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock. Mon, Jun. 09, 2025
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2025 Earnings Conference Call May 13, 2025 9:00 AM ET Company Participants Louisa Smith - IR, Gilmartin Group John Erb - Chairman & Interim CEO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - ROTH Operator Good day, everyone, and welcome to Nuwellis First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. Tue, May. 13, 2025
Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $20.98 per share a year ago. Tue, May. 13, 2025
Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Tue, May. 13, 2025
Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHO WHAT WHERE WHEN WHY Nuwellis, Inc. (Nasdaq: NUWE) and KDI Precision Manufacturing Outsourcing manufacturing and assembly of key Aquadex product components. Mon, May. 12, 2025

Transcripts

Transcipts Data
Nuwellis, Inc. (NUWE) on Q1 2025 Results - Earnings Call Transcript SA Transcripts Tue, May. 13, 2025
Nuwellis, Inc. (NUWE) on Q4 2024 Results - Earnings Call Transcript SA Transcripts Tue, Mar. 11, 2025
Nuwellis, Inc. (NUWE) on Q3 2024 Results - Earnings Call Transcript SA Transcripts Mon, Nov. 11, 2024
Nuwellis, Inc. (NUWE) on Q2 2024 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 13, 2024
Nuwellis, Inc. (NUWE) on Q1 2024 Results - Earnings Call Transcript SA Transcripts Tue, May. 07, 2024
Nuwellis, Inc. (NUWE) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Tue, Mar. 05, 2024
Nuwellis, Inc. (NUWE) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Tue, Nov. 07, 2023
Nuwellis, Inc. (NUWE) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 08, 2023
Nuwellis, Inc. (NUWE) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Tue, May. 09, 2023
Nuwellis, Inc. (NUWE) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Tue, Feb. 28, 2023
Nuwellis, Inc. (NUWE) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Tue, Nov. 08, 2022
Nuwellis, Inc. (NUWE) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 09, 2022
Nuwellis, Inc. (NUWE) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Tue, May. 10, 2022
Nuwellis, Inc. (NUWE) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Tue, Mar. 01, 2022
Nuwellis, Inc. (NUWE) on Q3 2021 Results - Earnings Call Transcript SA Transcripts Tue, Nov. 09, 2021
Nuwellis, Inc. (NUWE) on Q2 2021 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 10, 2021
Nuwellis, Inc. (NUWE) on Q1 2021 Results - Earnings Call Transcript SA Transcripts Fri, May. 14, 2021

SEC Filings

SEC Filings
Nuwellis, Inc. (NUWE) - SCHEDULE 13D SEC Filings 06/16/2025
Nuwellis, Inc. (NUWE) - SCHEDULE 13G SEC Filings 06/13/2025
Nuwellis, Inc. (NUWE) - SCHEDULE 13G SEC Filings 06/12/2025
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/11/2025
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 06/10/2025
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 06/10/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/09/2025
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 06/03/2025
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 05/30/2025
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/29/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/22/2025
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/21/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/13/2025
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/13/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/12/2025
Nuwellis, Inc. (NUWE) - DEFR14A SEC Filings 05/09/2025
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/14/2025
Nuwellis, Inc. (NUWE) - ARS SEC Filings 04/14/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/03/2025
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 04/01/2025
Nuwellis, Inc. (NUWE) - SCHEDULE 13G/A SEC Filings 03/18/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/11/2025
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/11/2025
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/24/2025
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 12/23/2024
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 12/20/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 12/19/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/19/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/16/2024
Nuwellis, Inc. (NUWE) - D SEC Filings 11/20/2024
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 11/15/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/12/2024
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/12/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/07/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/01/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/23/2024
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 09/09/2024
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 09/06/2024
Nuwellis, Inc. (NUWE) - D SEC Filings 09/04/2024
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 08/30/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 08/29/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/26/2024
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 08/26/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/22/2024
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 08/15/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/13/2024
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/13/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/12/2024
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 08/02/2024
Nuwellis, Inc. (NUWE) - D SEC Filings 08/02/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/25/2024
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 07/25/2024
Nuwellis, Inc. (NUWE) - 8-K/A - Current report SEC Filings 07/17/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/17/2024
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 07/10/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/03/2024
Nuwellis, Inc. (NUWE) - S-3 SEC Filings 07/01/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/26/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/10/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/06/2024
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/29/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/29/2024
Nuwellis, Inc. (NUWE) - DEFR14A SEC Filings 05/17/2024
Nuwellis, Inc. (NUWE) - ARS SEC Filings 05/17/2024
Nuwellis, Inc. (NUWE) - PRER14A SEC Filings 05/08/2024
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/08/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/07/2024
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 05/06/2024
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 05/03/2024
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 05/01/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/01/2024
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 04/29/2024
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 04/29/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 04/17/2024
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 04/09/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/26/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 03/13/2024
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/11/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/06/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 02/08/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/06/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 02/05/2024
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 01/31/2024
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 01/18/2024
Nuwellis, Inc. (NUWE) - 8-K/A - Current report SEC Filings 01/09/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/08/2024
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/04/2024
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/13/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/07/2023
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/07/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/01/2023
Nuwellis, Inc. (NUWE) - 3 SEC Filings 11/01/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/17/2023
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 10/16/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/10/2023
Nuwellis, Inc. (NUWE) - POS462C SEC Filings 10/06/2023
Nuwellis, Inc. (NUWE) - AW SEC Filings 10/05/2023
Nuwellis, Inc. (NUWE) - POS AM SEC Filings 10/04/2023
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 10/02/2023
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 09/29/2023
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 09/21/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/06/2023
Nuwellis, Inc. (NUWE) - 3 SEC Filings 09/06/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/18/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/08/2023
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/08/2023
Nuwellis, Inc. (NUWE) - D SEC Filings 06/26/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/21/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/05/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/05/2023
Nuwellis, Inc. (NUWE) - 3 SEC Filings 06/05/2023
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/25/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/23/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/22/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/09/2023
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/09/2023
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/07/2023
Nuwellis, Inc. (NUWE) - ARS SEC Filings 04/07/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/16/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/14/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/07/2023
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 03/03/2023
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/03/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/01/2023
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/13/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/18/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/09/2023
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/09/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/05/2023
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/29/2022
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 12/28/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/27/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/09/2022
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 12/08/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/08/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/06/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/30/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/08/2022
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/08/2022
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 11/07/2022
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 10/28/2022
Nuwellis, Inc. (NUWE) - 3 SEC Filings 10/28/2022
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 10/20/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/18/2022
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 10/18/2022
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 10/17/2022
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 10/14/2022
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 10/14/2022
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 10/14/2022
Nuwellis, Inc. (NUWE) - S-1MEF SEC Filings 10/13/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 10/13/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 10/12/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 10/11/2022
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 10/11/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 10/06/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/06/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/05/2022
Nuwellis, Inc. (NUWE) - FWP SEC Filings 10/03/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/03/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 09/30/2022
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 09/29/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/27/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/23/2022
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 09/15/2022
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 09/09/2022
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/11/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/09/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/03/2022
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/26/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/26/2022
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/26/2022
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 05/18/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/18/2022
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 05/17/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/17/2022
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/12/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/10/2022
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 04/21/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/21/2022
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/11/2022
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/08/2022
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/04/2022
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/03/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/01/2022
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/08/2022
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/03/2022
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 01/20/2022
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/23/2021
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/10/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/09/2021
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 09/20/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/17/2021
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 09/15/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/09/2021
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 09/03/2021
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/20/2021
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/12/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/10/2021
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 07/06/2021
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 07/02/2021
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 07/01/2021
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/01/2021
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 06/30/2021
Nuwellis, Inc. (NUWE) - 3 SEC Filings 06/29/2021
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 06/28/2021
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 06/24/2021
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/23/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/22/2021
Nuwellis, Inc. (NUWE) - S-3/A SEC Filings 06/21/2021
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 06/21/2021
Nuwellis, Inc. (NUWE) - 3 SEC Filings 06/16/2021
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 06/14/2021
Nuwellis, Inc. (NUWE) - S-3 SEC Filings 06/04/2021
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/27/2021
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 05/24/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/20/2021
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/20/2021
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/13/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/11/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/27/2021
Nuwellis, Inc. (NUWE) - 3 SEC Filings 04/16/2021
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/13/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/05/2021
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 03/25/2021
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/25/2021
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 03/24/2021
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 03/23/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/17/2021
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 03/17/2021
Nuwellis, Inc. (NUWE) - S-3MEF SEC Filings 03/16/2021
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 03/16/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/03/2021
Nuwellis, Inc. (NUWE) - 8-K/A - Current report SEC Filings 02/25/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/23/2021
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/16/2021
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/09/2021
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/26/2021
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/19/2021
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 01/13/2021
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/12/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/10/2020
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 10/29/2020
Nuwellis, Inc. (NUWE) - 8-K/A - Current report SEC Filings 10/16/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/16/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/09/2020
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 09/11/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/01/2020
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 08/28/2020
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 08/25/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/21/2020
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 08/19/2020
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 08/19/2020
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 08/17/2020
Nuwellis, Inc. (NUWE) - FWP SEC Filings 08/17/2020
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 08/17/2020
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 08/12/2020
Nuwellis, Inc. (NUWE) - 3 SEC Filings 08/10/2020
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 08/06/2020
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/05/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/04/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/25/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/19/2020
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 06/09/2020
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 06/09/2020
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 06/05/2020
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 06/04/2020
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 06/04/2020
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/29/2020
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 05/29/2020
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 05/22/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/22/2020
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/22/2020
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 05/15/2020
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/14/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/12/2020
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 05/11/2020
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 05/11/2020
Nuwellis, Inc. (NUWE) - D SEC Filings 05/07/2020
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 05/06/2020
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 05/06/2020
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 05/05/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/04/2020
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 05/04/2020
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 04/29/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/23/2020
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 04/17/2020
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/13/2020
Nuwellis, Inc. (NUWE) - PRER14A SEC Filings 04/08/2020
Nuwellis, Inc. (NUWE) - D SEC Filings 04/08/2020
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 04/01/2020
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 03/31/2020
Nuwellis, Inc. (NUWE) - D SEC Filings 03/30/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/30/2020
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 03/24/2020
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 03/23/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/20/2020
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/05/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/03/2020
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/14/2020
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/12/2020
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 02/05/2020
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 02/03/2020
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/29/2020
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 01/29/2020
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 01/27/2020
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 01/27/2020
Nuwellis, Inc. (NUWE) - S-1MEF SEC Filings 01/24/2020
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 01/23/2020
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 01/23/2020
Nuwellis, Inc. (NUWE) - FWP SEC Filings 01/08/2020
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 01/08/2020
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 01/06/2020
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 12/31/2019
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 12/31/2019
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 12/27/2019
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 12/27/2019
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 12/27/2019
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 12/20/2019
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 12/20/2019
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 12/20/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/20/2019
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 12/13/2019
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 12/06/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/06/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 11/27/2019
Nuwellis, Inc. (NUWE) - D SEC Filings 11/21/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 11/14/2019
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/08/2019
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 11/07/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/05/2019
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 11/05/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/04/2019
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 11/01/2019
Nuwellis, Inc. (NUWE) - D SEC Filings 11/01/2019
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 10/25/2019
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 10/24/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/23/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/27/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/24/2019
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/16/2019
Nuwellis, Inc. (NUWE) - 3 SEC Filings 09/13/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/04/2019
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 08/08/2019
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/08/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/06/2019
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/31/2019
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/28/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/24/2019
Nuwellis, Inc. (NUWE) - 3 SEC Filings 05/17/2019
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/09/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/07/2019
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/09/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 03/18/2019
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 03/15/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/13/2019
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 03/13/2019
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/12/2019
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 03/08/2019
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 03/08/2019
Nuwellis, Inc. (NUWE) - S-1MEF SEC Filings 03/07/2019
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 03/06/2019
Nuwellis, Inc. (NUWE) - FWP SEC Filings 03/01/2019
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 02/25/2019
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 02/21/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/20/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/14/2019
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 02/05/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/25/2019
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 01/22/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 01/17/2019
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 01/07/2019
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/02/2019
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 12/31/2018
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 11/30/2018
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 11/19/2018
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/07/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/06/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/13/2018
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/09/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/07/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/03/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/25/2018
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 07/06/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/06/2018
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 07/05/2018
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 07/03/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/03/2018
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 07/03/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/29/2018
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 06/29/2018
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/30/2018
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 05/29/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/29/2018
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 05/24/2018
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 05/22/2018
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 05/21/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/18/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/18/2018
Nuwellis, Inc. (NUWE) - S-3 SEC Filings 05/11/2018
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/10/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/08/2018
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/06/2018
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 03/23/2018
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/22/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/20/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/19/2018
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/18/2018
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 01/08/2018
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/05/2018
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 12/08/2017
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 11/29/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/29/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/28/2017
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 11/22/2017
Nuwellis, Inc. (NUWE) - S-1MEF SEC Filings 11/22/2017
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 11/22/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 11/20/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 11/17/2017
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 11/17/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 11/13/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 11/06/2017
Nuwellis, Inc. (NUWE) - FWP SEC Filings 11/06/2017
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/02/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/31/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/30/2017
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 10/18/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/13/2017
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 10/12/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/12/2017
Nuwellis, Inc. (NUWE) - SC 13D/A SEC Filings 09/20/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/20/2017
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 09/08/2017
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 08/18/2017
Nuwellis, Inc. (NUWE) - SC 13D/A SEC Filings 08/17/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/16/2017
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/10/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/08/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/09/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/06/2017
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 06/02/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/02/2017
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/30/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/30/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/23/2017
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/12/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/09/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/05/2017
Nuwellis, Inc. (NUWE) - 3 SEC Filings 05/02/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/28/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/25/2017
Nuwellis, Inc. (NUWE) - SC 13D/A SEC Filings 04/20/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 04/20/2017
Nuwellis, Inc. (NUWE) - 3 SEC Filings 04/20/2017
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 04/19/2017
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 04/19/2017
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 04/18/2017
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/13/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/11/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 04/06/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 04/05/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 03/29/2017
Nuwellis, Inc. (NUWE) - FWP SEC Filings 03/29/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/29/2017
Nuwellis, Inc. (NUWE) - SC 13D/A SEC Filings 03/28/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/24/2017
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 03/22/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/22/2017
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 03/22/2017
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 03/21/2017
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 03/20/2017
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 03/15/2017
Nuwellis, Inc. (NUWE) - SC 13D SEC Filings 03/10/2017
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/08/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/03/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/03/2017
Nuwellis, Inc. (NUWE) - 3 SEC Filings 03/03/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/02/2017
Nuwellis, Inc. (NUWE) - D SEC Filings 02/27/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/16/2017
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 02/14/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/10/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/09/2017
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/09/2017
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/07/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/03/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/01/2017
Nuwellis, Inc. (NUWE) - D SEC Filings 01/25/2017
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 01/20/2017
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 01/19/2017
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/17/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/13/2017
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/10/2017
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 01/03/2017
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 01/03/2017
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 12/30/2016
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 12/28/2016
Nuwellis, Inc. (NUWE) - DEFA14A SEC Filings 12/21/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/21/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/16/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 12/16/2016
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 12/15/2016
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 12/08/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/29/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/22/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/17/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/17/2016
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 11/14/2016
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/14/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/10/2016
Nuwellis, Inc. (NUWE) - D SEC Filings 11/09/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/08/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/03/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/31/2016
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 10/31/2016
Nuwellis, Inc. (NUWE) - 8-K/A - Current report SEC Filings 10/21/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/17/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/29/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/23/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/16/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/24/2016
Nuwellis, Inc. (NUWE) - D SEC Filings 08/18/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/17/2016
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/11/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/09/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/08/2016
Nuwellis, Inc. (NUWE) - D SEC Filings 08/02/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/25/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/22/2016
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 07/22/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/18/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/11/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/16/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/15/2016
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/31/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/31/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/31/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/16/2016
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/05/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/03/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 04/18/2016
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/13/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/25/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/17/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/16/2016
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 03/15/2016
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/15/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/08/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/03/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/02/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/17/2016
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/11/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/20/2016
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/15/2016
Nuwellis, Inc. (NUWE) - 3 SEC Filings 01/13/2016
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 12/09/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/30/2015
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/05/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/03/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/13/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/08/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/31/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/14/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/13/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/11/2015
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/05/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/04/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/03/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/23/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/06/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/30/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/25/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/03/2015
Nuwellis, Inc. (NUWE) - SD SEC Filings 06/01/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/26/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/26/2015
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/07/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/05/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/04/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/23/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/17/2015
Nuwellis, Inc. (NUWE) - ARS SEC Filings 04/15/2015
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/10/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 04/02/2015
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 03/20/2015
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/20/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/17/2015
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 03/06/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/06/2015
Nuwellis, Inc. (NUWE) - D SEC Filings 03/02/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/02/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/25/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/19/2015
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/17/2015
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/06/2015
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 02/03/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/02/2015
Nuwellis, Inc. (NUWE) - 3/A SEC Filings 01/13/2015
Nuwellis, Inc. (NUWE) - 3 SEC Filings 01/13/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/12/2015
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/07/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/06/2015
Nuwellis, Inc. (NUWE) - 3 SEC Filings 01/06/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/02/2015
Nuwellis, Inc. (NUWE) - 4 SEC Filings 12/02/2014
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 11/06/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/05/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/03/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/03/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/31/2014
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 10/31/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/10/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/02/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/01/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/16/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/15/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/09/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/03/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/03/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/29/2014
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/12/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/11/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/05/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/30/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/14/2014
Nuwellis, Inc. (NUWE) - 3 SEC Filings 07/14/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 07/09/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/30/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/10/2014
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 06/06/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/04/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 06/02/2014
Nuwellis, Inc. (NUWE) - SD SEC Filings 05/30/2014
Nuwellis, Inc. (NUWE) - POS AM SEC Filings 05/30/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/30/2014
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/13/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/09/2014
Nuwellis, Inc. (NUWE) - 3 SEC Filings 05/07/2014
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 05/06/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/01/2014
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/11/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 04/09/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 04/01/2014
Nuwellis, Inc. (NUWE) - S-3 SEC Filings 03/21/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/21/2014
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 03/18/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/18/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/14/2014
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/14/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/10/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/05/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 03/04/2014
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/14/2014
Nuwellis, Inc. (NUWE) - 5 SEC Filings 02/12/2014
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/11/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/11/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/30/2014
Nuwellis, Inc. (NUWE) - 5/A SEC Filings 01/21/2014
Nuwellis, Inc. (NUWE) - 5 SEC Filings 01/16/2014
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 01/16/2014
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/13/2014
Nuwellis, Inc. (NUWE) - 4 SEC Filings 01/10/2014
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/12/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/31/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 10/29/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 10/23/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/19/2013
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 09/19/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/18/2013
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 09/18/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/10/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/10/2013
Nuwellis, Inc. (NUWE) - 3 SEC Filings 09/05/2013
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 08/09/2013
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 08/08/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/01/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 06/14/2013
Nuwellis, Inc. (NUWE) - 8-A12B SEC Filings 06/14/2013
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 05/30/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/29/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/28/2013
Nuwellis, Inc. (NUWE) - D SEC Filings 05/20/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/15/2013
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/14/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 05/07/2013
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 04/22/2013
Nuwellis, Inc. (NUWE) - 424B5 SEC Filings 04/12/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/11/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/10/2013
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 04/10/2013
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 04/08/2013
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 04/05/2013
Nuwellis, Inc. (NUWE) - S-3/A SEC Filings 04/02/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 04/02/2013
Nuwellis, Inc. (NUWE) - 3 SEC Filings 03/26/2013
Nuwellis, Inc. (NUWE) - S-3 SEC Filings 03/15/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/13/2013
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/12/2013
Nuwellis, Inc. (NUWE) - 424B3 SEC Filings 02/19/2013
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 02/15/2013
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 02/14/2013
Nuwellis, Inc. (NUWE) - SC 13G/A SEC Filings 02/14/2013
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 02/13/2013
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/13/2013
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 02/08/2013
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/08/2013
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/08/2013
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 02/06/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/06/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/05/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/04/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 02/01/2013
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 01/28/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/16/2013
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 01/07/2013
Nuwellis, Inc. (NUWE) - 4 SEC Filings 12/17/2012
Nuwellis, Inc. (NUWE) - 4 SEC Filings 11/14/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 11/13/2012
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 11/09/2012
Nuwellis, Inc. (NUWE) - D SEC Filings 09/19/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 09/18/2012
Nuwellis, Inc. (NUWE) - 4 SEC Filings 09/18/2012
Nuwellis, Inc. (NUWE) - 3 SEC Filings 09/18/2012
Nuwellis, Inc. (NUWE) - S-8 SEC Filings 09/14/2012
Nuwellis, Inc. (NUWE) - 4/A SEC Filings 08/23/2012
Nuwellis, Inc. (NUWE) - 4 SEC Filings 08/20/2012
Nuwellis, Inc. (NUWE) - EFFECT SEC Filings 08/10/2012
Nuwellis, Inc. (NUWE) - 424B4 SEC Filings 08/10/2012
Nuwellis, Inc. (NUWE) - S-1MEF SEC Filings 08/09/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 08/09/2012
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 08/08/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 08/08/2012
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 08/01/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 08/01/2012
Nuwellis, Inc. (NUWE) - S-1/A SEC Filings 07/30/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 07/30/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 07/30/2012
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 07/30/2012
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 07/27/2012
Nuwellis, Inc. (NUWE) - DEF 14A SEC Filings 07/27/2012
Nuwellis, Inc. (NUWE) - PRER14A SEC Filings 07/26/2012
Nuwellis, Inc. (NUWE) - S-1 SEC Filings 07/17/2012
Nuwellis, Inc. (NUWE) - PRE 14A SEC Filings 07/17/2012
Nuwellis, Inc. (NUWE) - 10-K/A - Current report SEC Filings 07/17/2012
Nuwellis, Inc. (NUWE) - 10-Q - Quarterly Report SEC Filings 05/14/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 05/10/2012
Nuwellis, Inc. (NUWE) - 3/A SEC Filings 05/10/2012
Nuwellis, Inc. (NUWE) - 3/A SEC Filings 05/02/2012
Nuwellis, Inc. (NUWE) - 10-K/A - Current report SEC Filings 04/30/2012
Nuwellis, Inc. (NUWE) - 10-K - Current report SEC Filings 03/23/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/15/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 03/12/2012
Nuwellis, Inc. (NUWE) - 3/A SEC Filings 03/06/2012
Nuwellis, Inc. (NUWE) - 3/A SEC Filings 03/02/2012
Nuwellis, Inc. (NUWE) - CT ORDER SEC Filings 02/28/2012
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/28/2012
Nuwellis, Inc. (NUWE) - SC 13G SEC Filings 02/23/2012
Nuwellis, Inc. (NUWE) - D SEC Filings 02/22/2012
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 02/16/2012
Nuwellis, Inc. (NUWE) - 8-K - Current report SEC Filings 02/16/2012
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/16/2012
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/15/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/14/2012
Nuwellis, Inc. (NUWE) - CERTNAS SEC Filings 02/14/2012
Nuwellis, Inc. (NUWE) - 3 SEC Filings 02/14/2012
Nuwellis, Inc. (NUWE) - 10-12B/A SEC Filings 02/14/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/13/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/08/2012
Nuwellis, Inc. (NUWE) - 10-12B/A SEC Filings 02/08/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 02/01/2012
Nuwellis, Inc. (NUWE) - 10-12B/A SEC Filings 02/01/2012
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 01/06/2012
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 12/29/2011
Nuwellis, Inc. (NUWE) - 10-12B/A SEC Filings 12/29/2011
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 12/23/2011
Nuwellis, Inc. (NUWE) - CORRESP SEC Filings 12/16/2011
Nuwellis, Inc. (NUWE) - 10-12B/A SEC Filings 12/16/2011
Nuwellis, Inc. (NUWE) - UPLOAD SEC Filings 10/27/2011
Nuwellis, Inc. (NUWE) - 10-12B SEC Filings 09/30/2011
Nuwellis, Inc. (NUWE) - D SEC Filings 08/10/2011
Nuwellis, Inc. (NUWE) - D SEC Filings 11/24/2010

Press Releases

StockPrice Release
Nuwellis appoints john erb as chief executive officer 07/02/2025
Nuwellis announces closing of $5.0 million underwritten public offering including full exercise of overallotment option 06/10/2025
Nuwellis announces pricing of $4.3 million underwritten public offering 06/09/2025
Nuwellis, inc. reports first quarter 2025 financial results and business highlights 05/13/2025
Nuwellis contracts with kdi precision manufacturing to strengthen production and improve operational efficiency 05/12/2025
Nuwellis expands aquadex® for pediatric fluid management to two new hospital systems 05/08/2025
Nuwellis expands ip portfolio with patent that reduces clinical burden, preserves precision 04/24/2025
Nuwellis, inc. to report first quarter 2025 financial results on may 13, 2025 04/22/2025
Nuwellis, inc. announces fourth quarter and full year 2024 financial results 03/11/2025
Nuwellis announces retirement of nestor jaramillo, jr. as president and ceo 02/24/2025
Jacc: heart failure paper reports promising findings of aquadex therapy in updated avoid-hf study analysis 02/20/2025
Nuwellis, inc. to report fourth quarter and full year 2024 financial results on march 11, 2025 02/18/2025
Nuwellis regains compliance with nasdaq listing requirements 12/19/2024
Nuwellis, inc. announces third quarter 2024 financial results and recent highlights 11/11/2024
Nuwellis announces exercise of warrants for $5.1 million of gross proceeds 11/05/2024
Nuwellis receives increased reimbursement rate for aquadex smartflow® therapy from the centers for medicare and medicaid 11/04/2024
Nuwellis announces preliminary results for third quarter of 2024 11/01/2024
Nuwellis welcomes university of iowa health care stead family children's hospital as newest pediatric customer 10/31/2024
Nuwellis, inc. to report third quarter 2024 financial results on november 11, 2024 10/23/2024
Nuwellis to present at the third annual roth healthcare opportunities conference 09/25/2024
Nuwellis announces pricing of $916,000 registered direct offering priced at-the-market under nasdaq rules 08/23/2024
Nuwellis, inc. announces second quarter 2024 financial results 08/13/2024
Nuwellis announces first pediatric patient treated in a commercial setting with seastar medical's quelimmune™ therapy at cincinnati children's 07/26/2024
Nuwellis announces pricing of $2.0 million offering priced at-the-market under nasdaq rules 07/24/2024
Nuwellis, inc. to report second quarter 2024 financial results on august 13, 2024 07/23/2024
Nuwellis marks first commercial sale of quelimmune™ therapy to cincinnati children's 07/17/2024
Nuwellis announces reverse stock split 06/26/2024
Nuwellis secures new patent for innovative pediatric continuous renal replacement therapy, vivian™ 06/25/2024
Nuwellis and davita extend supply and collaboration agreement pilot phase 06/06/2024
Nuwellis announces expansion of ultrafiltration program to pediatric patients at one of the largest hospital networks in florida 05/14/2024
Nuwellis announces purchase agreement with a 50 hospital network for aquadex ultrafiltration therapy 05/09/2024
Nuwellis, inc. announces first quarter 2024 financial results 05/07/2024
Nuwellis announces closing of $2.7 million public offering 04/30/2024
Nuwellis, inc. to report first quarter 2024 financial results on may 7, 2024 04/30/2024
Nuwellis announces pricing of $2.7 million public offering 04/26/2024
Late-breaking data highlighting benefits of ultrafiltration therapy using the aquadex system for heart failure patients was presented at the technology and heart failure therapeutics conference 03/07/2024
Nuwellis, inc. announces fourth quarter and full year 2023 financial results 03/05/2024
Nuwellis, inc. to report fourth quarter and full year 2023 financial results on march 5, 2024 02/27/2024
Nuwellis' distribution partner, seastar medical, receives fda humanitarian device exemption for pediatric selective cytopheretic device quelimmune™ 02/22/2024
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 02/20/2024
Nuwellis to announce late-breaking clinical data and host satellite symposium at technology and heart failure therapeutics conference 02/20/2024
New case series demonstrates potential of aquadex therapy for end-stage liver disease patients with fluid overload 02/06/2024
Nuwellis receives fda clearance for an additional dual lumen extended length peripheral catheter 01/04/2024
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 11/14/2023
Nuwellis, inc. announces third quarter 2023 financial results 11/07/2023
Nuwellis, inc. to announce third quarter 2023 financial results on november 7, 2023 10/18/2023
Nuwellis announces closing of $2.25 million public offering of series j convertible redeemable preferred stock and warrants 10/17/2023
Nuwellis announces pricing of $2.25 million public offering of series j convertible redeemable preferred stock and warrants 10/13/2023
Nuwellis provides regulatory update on seastar medical's selective cytopheretic device use in pediatric acute kidney injury under a humanitarian device exemption 10/10/2023
Nuwellis to present at the gilmartin group emerging growth showcase 09/11/2023
Nuwellis, inc. announces second quarter 2023 financial results 08/08/2023
Nuwellis announces plan for cfo transition 08/08/2023
Nuwellis, inc. to announce second quarter 2023 financial results on august 8, 2023 07/18/2023
Nuwellis to participate in the maxim group virtual healthcare conference 06/13/2023
Nuwellis announces the appointment of mike mccormick to its board of directors 06/05/2023
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 05/22/2023
Nuwellis, inc. announces first quarter 2023 financial results 05/09/2023
Nuwellis announces peer-reviewed publication of clinical trials analysis advocating the use of ultrafiltration for heart failure patients resistant to diuretics 03/21/2023
Nuwellis, inc. announces fourth quarter and full year 2022 financial results 02/28/2023
Nuwellis to present at the oppenheimer 33rd annual healthcare conference 02/23/2023
Nuwellis, inc. to announce fourth quarter and full year 2022 financial results on february 28, 2023 02/07/2023
Nuwellis appoints dr. john jefferies as chief medical officer 01/05/2023
Nuwellis, inc. announces passage of warrant proposal 01/04/2023
Seastar medical and nuwellis enter into a u.s. license and distribution agreement for seastar medical's selective cytopheretic device (scd) for pediatric acute kidney injury (aki) 12/29/2022
Nuwellis, inc. announces compliance with nasdaq listing requirements 12/27/2022
Nuwellis, inc. announces adjournment of special meeting of stockholders due to lack of quorum 12/08/2022
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 11/18/2022
Nuwellis, inc. reports third quarter 2022 financial results 11/08/2022
Nuwellis, inc. to announce third quarter 2022 financial results on november 8, 2022 10/19/2022
Nuwellis announces appointment of chief financial officer 10/19/2022
Nuwellis announces closing of $11.04 million underwritten public offering including full exercise of overallotment option 10/18/2022
Nuwellis announces pricing of $9.6 million upsized underwritten public offering 10/14/2022
Nuwellis announces data demonstrating statistically superior clinical benefit of aquadex therapy in reducing heart failure events and mortality at the 2022 hfsa meeting 10/03/2022
Nuwellis announces the activation of new sites for its pivotal reverse-hf trial 09/27/2022
U.s. patent and trademark office awards nuwellis patent for innovative pediatric technology 08/25/2022
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 08/19/2022
Nuwellis inc. to present at the inaugural gilmartin group emerging growth company showcase 08/19/2022
Nuwellis, inc. announces second quarter 2022 financial results 08/09/2022
Nuwellis announces the submission of the avoid-hf clinical analysis as a late breaking clinical trial at hfsa 07/26/2022
Nuwellis, inc. to announce second quarter 2022 financial results on august 9, 2022 07/14/2022
Nuwellis initiates its outpatient heart failure strategy using aquadex ultrafiltration therapy 07/12/2022
Nuwellis announces first patient enrolled in its pivotal trial reverse-hf 06/29/2022
Nuwellis expands pediatric access to ultrafiltration therapy at hospitals in florida and arkansas 06/14/2022
Nuwellis, inc. announces adjournment of annual meeting of stockholders due to lack of quorum 05/17/2022
Nuwellis, inc. announces first quarter 2022 financial results 05/10/2022
Nuwellis announces presentation of aquadex®-related abstracts at the 2022 pediatric academic societies meeting 05/09/2022
Nuwellis announces irb approval to begin its reverse-hf clinical study 03/15/2022
Nuwellis, inc. announces fourth quarter and full year 2021 financial results 03/01/2022
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 02/22/2022
Nuwellis initiates reverse-hf study to evaluate ultrafiltration for heart failure patients with fluid overload 02/17/2022
Nuwellis, inc. to announce fourth quarter 2021 financial results on march 1, 2022 02/01/2022
New category iii cpt code for the nuwellis aquadex ultrafiltration system is now in effect 01/25/2022
Nuwellis, inc. reports inducement grant under nasdaq listing rule 5635(c)(4) 11/19/2021
Nuwellis, inc. announces third quarter 2021 financial results 11/09/2021
Aquadex smartflow® system by nuwellis selected as a 2021 r&d 100 awards winner 11/04/2021
Nuwellis, inc. to announce third quarter 2021 financial results on november 9, 2021 10/14/2021
Nuwellis receives ce mark for 24-hour blood circuit set 09/21/2021
Nuwellis, inc. announces closing of $10.0 million underwritten public offering of common stock including full exercise of over-allotment option 09/17/2021
Nuwellis, inc. announces pricing of $8.7 million underwritten public offering of common stock 09/15/2021
Nuwellis, inc. announces proposed underwritten public offering of common stock 09/14/2021
Nuwellis inc. to speak at upcoming investor conferences 08/31/2021
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 08/24/2021
Nuwellis inc. to participate at the 2021 ladenburg thalmann healthcare conference 07/06/2021
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 07/01/2021
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 06/24/2021
Nuwellis, inc. reports inducement grants under nasdaq listing rule 5635(c)(4) 05/20/2021
Nuwellis provides more children in texas with access to its unique fluid management technology 05/13/2021

More Headlines

News
Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach. 05/08/2025
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent and Trademark Office. The newly granted patent covers a fluid bag design that passively drains once full—reducing the need for manual intervention by clinical staff while preserving the system's precise weight-based measurement. 04/24/2025
Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025 MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 04/22/2025
Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2024 Earnings Conference Call March 11, 2025 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations John Erb - Interim President and Chief Executive Officer Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to Nuwellis Earnings Conference Call for the Fourth Quarter and Full Year ended December 31, 2024. 03/11/2025
Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $78.32 per share a year ago. 03/11/2025
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. 03/11/2025
Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO John Erb, Current Chair of the Board, Appointed Interim President and CEO John Erb, Current Chair of the Board, Appointed Interim President and CEO 02/24/2025
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis MINNEAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today highlighted promising findings from an updated analysis of the AVOID-HF study, recently published in the Journal of the American College of Cardiology: Heart Failure. The analysis, led by Dr. Sean P. Pinney, Chief of Cardiology at Mount Sinai Morningside and Chief of Nephrology at Lenox Hill Hospital, Dr. Maria V. DeVita, provides new insights suggesting the potential benefits of Aquadex® SmartFlow ultrafiltration therapy in managing heart failure. The analysis found that patients treated with Aquadex therapy demonstrated a 60% reduction in heart failure events at 30 days compared to those receiving traditional IV diuretics. 02/20/2025
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025 MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 02/18/2025
Nuwellis Regains Compliance with Nasdaq Listing Requirements MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Common Stock will continue to trade on The Nasdaq Capital Market tier of Nasdaq under the symbol "NUWE". 12/19/2024
Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2024 Earnings Call Transcript November 11, 2024 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - CMO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good day, everyone, and Welcome to Nuwellis' Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. 11/11/2024
Nuwellis, Inc. (NUWE) Q3 Earnings Surpass Estimates Nuwellis, Inc. (NUWE) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of a loss of $0.88 per share. This compares to loss of $63.29 per share a year ago. 11/11/2024
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. 11/11/2024
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. 11/05/2024
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reimbursement level most consistent with administration of ultrafiltration therapy and cost of treatment. Effective January 1, 2025, the payment rate will increase 397% from $413 to $1,639 per day. 11/04/2024
Nuwellis Announces Preliminary Results for Third Quarter of 2024 MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. 11/01/2024
Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family Children's Hospital in Iowa City, Iowa, has adopted the Aquadex SmartFlow® system to treat pediatric patients suffering from fluid overload due to heart and kidney disease. 10/31/2024
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024 MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 10/23/2024
Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners' third annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024. 09/25/2024
Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 496,901 shares of the Company's common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. 08/23/2024
Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2024 Earnings Conference Call August 13, 2024 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations Nestor Jaramillo - President, CEO & Director Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to the Nuwellis Earnings Conference Call for the Second Quarter ended June 30th, 2024. 08/13/2024
Nuwellis, Inc. Announces Second Quarter 2024 Financial Results MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2024. 08/13/2024
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that the first patient has been treated with the newly launched QUELIMMUNE™ therapy in a commercial setting at Cincinnati Children's. QUELIMMUNE, manufactured for SeaStar Medical (Nasdaq: ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis, is a novel therapy designed to treat pediatric patients (weighing 10 kg or more) suffering from acute kidney injury (AKI) with sepsis or a septic condition and requiring kidney replacement therapy (KRT). 07/26/2024
Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS, July 24, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of $4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. 07/24/2024
Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter of 2024 on Tuesday, August 13, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 07/23/2024
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's MINNEAPOLIS, July 17, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to announce its first commercial sale of QUELIMMUNE™, a novel therapy developed by SeaStar Medical Holding Corporation for pediatric patients suffering from an uncontrolled inflammatory response triggered by their immune systems, to Cincinnati Children's. We believe this milestone marks a significant advancement in pediatric critical care and underscores Nuwellis' commitment to revolutionizing pediatric patient outcomes. 07/17/2024
Nuwellis Announces Reverse Stock Split MINNEAPOLIS, June 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, announced today a 1-for-35 reverse split (the “Reverse Stock Split”) of its common stock, par value $0.0001 (the “Common Stock”), effective at 5:00 pm Eastern Time June 27, 2024. Beginning on June 28, 2024, the Company's Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis. 06/26/2024
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™ MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent grant of a new patent from the United States Patent and Trademark Office (USPTO) related to its groundbreaking pediatric continuous renal replacement therapy (CRRT), Vivian™. This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This is the second of several forthcoming patents for Vivian, underscoring Nuwellis' commitment to development of novel technology designed to improve treatment options for critically ill children. 06/25/2024
DaVita, Nuwellis Extend Pilot Collaboration for Aquadex DaVita DVA recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis NUWE until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years. 06/11/2024
Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to August 31, 2024 Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to August 31, 2024 06/06/2024
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to its current heart failure and critical care patients. 05/14/2024
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. 05/09/2024
Nuwellis, Inc. Announces First Quarter 2024 Financial Results MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. 05/07/2024
Nuwellis Announces Closing of $2.7 Million Public Offering MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price of $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. 04/30/2024
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024 MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 04/30/2024
Nuwellis Announces Pricing of $2.7 Million Public Offering MINNEAPOLIS, April 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) is being sold together with one warrant to purchase one and a half shares of common stock. The warrants will have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. 04/26/2024
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference - Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events 03/07/2024
Nuwellis, Inc. (NUWE) Q4 2023 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2023 Results Conference Call March 5, 2024 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President, CEO Rob Scott - CFO John Jefferies - CMO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Operator Good morning, everyone, and welcome to the Nuwellis Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note, today's event is being recorded. 03/05/2024
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts 03/05/2024
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. 02/27/2024
Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received Humanitarian Device Exemption (HDE) from the U.S. Food and Drug Administration (FDA) for Quelimmune™, its pediatric Selective Cytopheretic Device. Quelimmune provides a new therapy option for children weighing 10 kg or more who have acute kidney injury (AKI) and sepsis or a septic condition requiring continuous kidney replacement therapy (CKRT) in a hospital intensive care unit. 02/22/2024
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company's independent directors approved equity awards under Nuwellis' 2021 Inducement Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan. 02/20/2024
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system 02/20/2024
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics 02/06/2024
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies 01/04/2024
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MINNEAPOLIS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective November 14, 2023, the Company's independent directors approved equity awards under Nuwellis' 2021 Inducement Plan, as material inducements to five individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan. 11/14/2023
Here's Why Nuwellis, Inc. (NUWE) Is a Great 'Buy the Bottom' Stock Now Nuwellis, Inc. (NUWE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. 11/13/2023
Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - Chief Medical Officer Rob Scott - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Nuwellis third-quarter 2023 earnings conference call. [Operator Instructions]. 11/07/2023
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023. 11/07/2023
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023 MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. 10/18/2023
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET. 09/11/2023
Why Is Nuwellis (NUWE) Stock Down Today? Nuwellis (NASDAQ: NUWE ) stock is taking a beating on Monday despite a lack of news concerning the medical device company. In fact, there's really not much in the way of anything to report about Nuwellis stock today. 09/11/2023
Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023 MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. 07/18/2023
Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. 02/23/2023
Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023 MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview. 02/07/2023
Buying Penny Stocks as 2022 Ends? 3 Tips and Tricks Use these tips for buying penny stocks right now The post Buying Penny Stocks as 2022 Ends? 3 Tips and Tricks appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/26/2022
Best Penny Stocks To Buy? 6 To Watch Under $1 Right Now Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy? 11/25/2022
Nuwellis, Inc. (NUWE) Q3 2022 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2022 Earnings Conference Call November 8, 2022 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President & Chief Executive Officer Lynn Blake - CFO Conference Call Participants Jeff Cohen - Ladenburg Thalmann Charlie Montang - Lake Street Capital Markets Operator Good day and welcome to the Nuwellis Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. 11/08/2022
Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022 MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. 10/19/2022
Nuwellis (NUWE) Stock: Why It Dropped 21.54% The stock price of Nuwellis (NUWE) dropped by 21.54% in the most recent trading session. This is why. 10/15/2022
Why Is Nuwellis (NUWE) Stock Up 110% Today? In a fresh news release, Nuwellis (NASDAQ: NUWE ) announced encouraging clinical data related to proprietary technology that could be deployed in cardiac surgery. The results were released in the Journal of Cardiac Surgery, and it is potentially good news for cardiac patients. 08/31/2022
Top Penny Stocks To Watch Before September 2022 Penny stocks are shares of companies trading for less than $5 and 08/31/2022
Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase MINNEAPOLIS, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:00 am ET. 08/19/2022
Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q2 2022 Results - Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2022 Earnings Conference Call August 9, 2022 9:00 AM ET Company Participants Matthew Bacso - Gilmartin Group LLC George Montague - Chief Financial Officer Nestor Jaramillo - President & Chief Executive Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day and thank you for standing by. Welcome to the Nuwellis, Inc. Second Quarter 2022 Earnings Conference Call. 08/09/2022
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022 MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit https://edge.media-server.com/mmc/p/frxpm437 [edge.media-server.com], or the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by registering through https://register.vevent.com/register/BIea28b3e149034b04b99b65da059db74a. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com. 07/14/2022
Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q1 2022 Results - Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2022 Earnings Conference Call May 10, 2022 9:00 AM ET Company Participants Matthew Bacso - Gilmartin Group Nestor Jaramillo - President, CEO & Director George Montague - CFO Conference Call Participants Destiny Buch - Ladenburg Thalmann & Co. Anthony Vendetti - Maxim Group Operator Good day and thank you for standing by. Welcome to the Nuwellis, Inc. First Quarter 2022 Earnings. 05/10/2022
Nuwellis' (NUWE) CEO Nestor Jaramillo on Q4 2021 Results - Earnings Call Transcript Nuwellis' (NUWE) CEO Nestor Jaramillo on Q4 2021 Results - Earnings Call Transcript 03/01/2022
Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022 MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its fourth quarter 2022 financial results will be released on Tuesday, March 1, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. 02/01/2022
Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q3 2021 Results - Earnings Call Transcript Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q3 2021 Results - Earnings Call Transcript 11/09/2021
Nuwellis, Inc. To Announce Third Quarter 2021 Financial Results on November 9, 2021 EDEN PRAIRIE, Minn., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), announced today that its third quarter 2021 financial results will be released on Tuesday, November 9, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. 10/14/2021
Nuwellis Stock Is Moving Higher After CE Mark for 24-Hour Blood Circuit Set Nuwellis Inc (NASDAQ:NUWE) has received CE Mark Certification for its 24-Hour Blood Circuit Set (UF 500-24 Hour) for the European Union. The UF 500-24 Hour blood circuit set is only to be used with the company's Aquadex SmartFlow system. 09/21/2021
Nuwellis Receives CE Mark for 24-Hour Blood Circuit Set Certification will help Nuwellis meet clinical and healthcare economic needs in Europe and make outpatient ultrafiltration treatment more accessible Certification will help Nuwellis meet clinical and healthcare economic needs in Europe and make outpatient ultrafiltration treatment more accessible 09/21/2021
Nuwellis, Inc. Announces Closing of $10.0 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option EDEN PRAIRIE, Minn., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the closing of its previously announced underwritten public offering of 4,005,588 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of approximately $10.0 million, including the full exercise of the underwriters' over-allotment option to purchase additional shares of the Company's common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. 09/17/2021
Why Nuwellis Shares Are Trading Lower Today Nuwellis (NASDAQ:NUWE) shares are trading lower after the company announced it priced a 3,483,120 share common stock offering at $2.50 per share. Nuwellis' stock has been falling Wednesday, down 28.46% to a price of $2.64. 09/15/2021
Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock EDEN PRAIRIE, Minn., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the pricing of an underwritten public offering of 3,483,120 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of approximately $8.7 million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters an option, exercisable in whole or in part for 45 days, to purchase up to an additional 522,468 shares of its common stock at the public offering price, less the underwriting discounts and commissions. 09/15/2021
Nuwellis, Inc. Announces Proposed Underwritten Public Offering of Common Stock EDEN PRAIRIE, Minn., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by the Company. The Company intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The Company intends to use the net proceeds for the offering for general corporate purposes, including the continued investment in commercialization efforts. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 09/14/2021
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EDEN PRAIRIE, Minn., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective August 18, 2021, the independent directors approved four equity awards under Nuwellis' 2021 Inducement Plan, as material inducement to four individuals entering into employment with the company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 08/24/2021
Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q2 2021 Results - Earnings Call Transcript Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q2 2021 Results - Earnings Call Transcript 08/10/2021
Nuwellis Inc. to Participate at the 2021 Ladenburg Thalmann Healthcare Conference EDEN PRAIRIE, Minn., July 06, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), a company focused on providing solutions for patients suffering from fluid overload, today announced that, Nestor Jaramillo, Chief Executive officer, and George Montague, Chief Financial Officer, are scheduled to participate in the 2021 Ladenburg Thalmann Healthcare Conference on Wednesday, July 14th, 2021. 07/06/2021
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EDEN PRAIRIE, Minn., July 01, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective June 30, 2021, the Compensation Committee of the Board of Directors approved an equity award to George Montague under Nuwellis' 2021 Inducement Plan, as a material inducement to Mr. Montague entering into employment with the company as its Chief Financial Officer and Treasurer. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 07/01/2021
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EDEN PRAIRIE, Minn., June 24, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective June 22, 2021, the independent directors approved four equity awards under Nuwellis' 2021 Inducement Plan, as material inducement to four individuals entering into employment with the company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 06/24/2021
NUWE Stock Price: Over 20% Increase Explanation The stock price of Nuwellis Inc (NASDAQ: NUWE) increased by over 20% during intraday trading. This is why it happened. 06/01/2021
3 Deep Value Benjamin Graham Style Stocks Benjamin Graham believed buying stocks at a deep discount to the value of their assets was a great way to achieve reduced risk and profits in the long run. 05/24/2021
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EDEN PRAIRIE, Minn., May 20, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective May 19, 2021, the independent directors approved eight equity awards under Nuwellis' 2021 Inducement Plan, as material inducement to an individual entering into employment with the company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 05/20/2021
Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q1 2021 Results - Earnings Call Transcript Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q1 2021 Results - Earnings Call Transcript 05/14/2021
Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology Gentle Ultrafiltration with Aquadex SmartFlow® Expands Options for Pediatric Patients Gentle Ultrafiltration with Aquadex SmartFlow® Expands Options for Pediatric Patients 05/13/2021

Unlock

NUWE Ratings Summary

NUWE Quant Ranking